2017
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco MR, Weckstein D, O’Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017, 317: 48-58. PMID: 28030702, PMCID: PMC5321662, DOI: 10.1001/jama.2016.19425.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBone and BonesBone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsDiphosphonatesDrug Administration ScheduleFemaleHumansImidazolesMaleMiddle AgedMultiple MyelomaPain MeasurementProstatic NeoplasmsSample SizeSpinal Cord CompressionSpinal FracturesZoledronic AcidConceptsSkeletal morbidity rateProportion of patientsDosing groupZoledronic acidBone metastasesMultiple myelomaProstate cancerBreast cancerSkeletal eventsKidney dysfunctionBone turnoverMorbidity rateClinical trialsEastern Cooperative Oncology Group performance statusOpen-label clinical trialEnd pointIncidence of osteonecrosisYear of randomizationPerformance status scorePrimary end pointSecondary end pointsBrief Pain InventoryMetastatic breast cancerMetastatic prostate cancerAcceptable treatment option
2010
Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysis
Sridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD. Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysis. American Journal Of Men's Health 2010, 4: 189-206. PMID: 20483872, DOI: 10.1177/1557988309353934.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalCancer-specific survivalProstate cancerAfrican American menWhite menCancer-related mortalityAmerican menUnadjusted studiesCause mortalityMeta-AnalysisSystematic reviewCancerSurvivalRacial differencesMenSignificant differencesMortalityLower survivalDifferences
2006
Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment
Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P. Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment. Molecular Pharmacology 2006, 71: 259-275. PMID: 17050804, DOI: 10.1124/mol.106.031153.Peer-Reviewed Original ResearchConceptsMitogen-activated protein kinase kinaseProtein kinase kinaseKinase 1/2 signalingOverexpression of BclDominant-negative AktInhibition of phosphatidylinositolCoA reductase inhibitor lovastatinPan-caspase inhibitorExpression of BclCancer cell survivalHMG-CoA reductase inhibitor lovastatinApoptosis-inducing factor expressionProstate cancer cell survivalTreatment of cellsEpidermal growth factor receptorDominant-negative IkappaBInhibition of erbB1Kinase kinaseReductase inhibitor lovastatinGeranylgeranyl transferase inhibitorPARP1 functionGrowth factor receptorCytotoxic effectsCaspase-9Prostate cancer cells
2002
Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma
Levine EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ. Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma. Cancer 2002, 94: 665-672. PMID: 11857298, DOI: 10.1002/cncr.10217.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaHigh dosesPelvic irradiationProstate carcinomaArm IFrequency of thrombocytopeniaLow-dose glucocorticoidsArm IIPhase II trialPhase III trialsPhase III testingMedian survival timeGranulocyte-macrophage colony-stimulating factorColony-stimulating factorAssessable patientsEstramustine combinationsII trialIII trialsMedian survivalPartial responsePSA valuesFavorable outcomeSurvival timePatientsSame schedule